본문 바로가기
KERD
논문KCI 등재

난소암에서 c-Abl, c-Kit, Platelet-derived Growth FactorReceptor (PDGFR)-α, PDGFR-β 의 발현과 예후의 관계

Correlations between the Expression of c-Abl, c-Kit, Plateletderived Growth Factor Receptor (PDGFR)-α and PDGFR-β and Survival in Patients with Ovarian Cancer

이근호|강창석|이교영|이희정
대한병리학회|2006.06|Journal of Pathology and Translational Medicine|제40권 제3호|pp. 210-216

1

조회

0

다운로드

0

인용

0

참고문헌

주제분류병리학

초록

Abstract

Background : Protein tyrosine kinases (PTKs) such as c-Abl, c-KIT, PDGFR-α and PDGFR-β are key proteins in the regulation of cell growth. In this study, we evaluated the correlations between the expression of c-Abl, c-KIT, PDGFR-α and PDGFR-β and the survival of patients with ovarian cancer. Methods : We performed the immunohistochemistry for 102 patients with ovarian cancer and we retrospectively reviewed the overall and disease free survival and also the response to platinum-based chemotherapy in those patients. Results : The short disease free survival rate was significantly associated with the increased expression of PDGFR-α (p= 0.0459). The short overall survival time in patients with advanced (stage III and IV) ovarian cancer was associated with the overexpression of c-Abl (p=0.0268) and the reduced expression of c-KIT (p=0.0307). On multivariate analysis, the tumor stage and c-Abl maintained their prognostic influence. Meanwhile, none of the four PTK expression patterns predicted the response to the platinum-based chemotherapy. Conclusions : Our data suggest that for patients with advanced ovarian cancer, the overexpression of c-Abl and the reduced expression of c- KIT might be used as poor prognostic factors for overall survival. It is further noteworthy that the tumor stage and c-Abl may be useful in predicting the patients’ survival. Although any of the four PTKs could not predict the response to platinum chemotherapy, the expression of the kinases targeted by tyrosine kinase inhibitor suggests the potential usefulness of imatinib mesylate for the treatment of ovarian cancer.

참고문헌 (24)

  1. "Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer", 98, pp.1176~1181 (2001)
  2. "CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival", 161, pp.1215~1221 (2002)
  3. "Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis", 89, pp.245~250 (2000)
  4. "Expression of c-ABL,c-KIT,and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium", 98, pp.758~764 (2003)
  5. "Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines", 93, pp.78~86 (2004)
  6. "Inhibition of KITtyrosine kinase activity:a novel molecular approach to the treatment of KIT-positive malignancies", 20, pp.1692~1703 (2002)
  7. "Role of KIT and platelet-derived growth factor receptors as oncoproteins", 31, pp.4~11 (2004)
  8. "An overview of translocation-related oncogenesis in the chronic myeloid leukaemias", 107, pp.57~63 (2002)
  9. "Expression and action of kit ligand", stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer, 2000, pp.62, 1600~1609
  10. "Paraffin section detection of the c-kit gene product value in the diagnosis of mast cell disorders", 29, pp.498~504 (1998)
  11. "Expression of c-kit protooncogene in human hepatocellular carcinoma", 217, pp.231~236 (2005)
  12. "Human ovariantumors of epithelial origin express PDGF in vitro and in vivo", 73, pp.60~64 (1994)
  13. "The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium", 71, pp.29~37 (1998)
  14. "Imatinib mesylate(Gleevec)inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation", 10, pp.681~690 (2004)
  15. "Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms", 53, pp.4550~4 (1993)
  16. "Expression of p73 and c-Abl proteins in human ovarian carcinomas", 70, pp.234~242 (2003)
  17. "Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials", 532, pp.141~151 (2003)
  18. "Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro", 2, pp.1~9 (2003)
  19. "Imatinib:A targeted clinical drug development", 40, pp.15~20 (2003)
  20. "Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571", 8, pp.3584~3591 (2002)
  21. "Cyclooxygenase-2 (COX-2) Epidermal growth factor receptor (EGFR) and Her-2", neu expression in ovarian cancer, 2002, pp.85, 305~310
  22. "Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma", 160, pp.893~903 (2002)
  23. "Primary and salvage therapy with LH-RHanalogues in ovarian cancer", 153, pp.83~94 (2000)
  24. "c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma:an immunocytochemical study", 15, pp.594~597 (2004)

관련 논문AI추천

비소세포폐암종에서 c-kit와 세포주기 조절인자의 발현주미, 김한성, 장선희대한병리학회 · Journal of Pathology and Translational Medicine2006 · 제40권 제6호유방조직의 c-kit와 COX-2의 발현과 의의고숙경, 김은경, 이원미, 주종은대한병리학회 · Journal of Pathology and Translational Medicine2008 · 제42권 제3호비인강암에서 c-kit 단백의 발현 및 유전자 변이의 임상적 의미강일규, 권순영, 김인선, 백승국, 우정수, 이세우, 이승훈, 정광윤, 조승현대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2007 · 제50권 제6호조직학적 위험 분류에 따른 위장관 간질종양에서 C-kit, DOG1, CD34, PKC-θ, PDGFR 발현의 비교김기성, 송강원, 송혜정, 신원섭대한임상검사과학회 · 대한임상검사과학회지2011 · 제43권 제2호상피성 난소암에서 HER-2/neu 단백 발현김기태, 김영남, 박영미, 서영진, 성문수, 손영실, 윤혜경, 이경복, 정대훈, 정수전, 조인호대한산부인과학회 · Obstetrics & Gynecology Science2006 · 제49권 제6호위장관 간질종양에서 c-kit유전자 돌연변이 및 면역조직화학적 발현강대영, 강동욱, 김경희, 김동훈, 김주헌, 박미자대한병리학회 · Journal of Pathology and Translational Medicine2003 · 제37권 제4호

이 간행물의 다른 논문 (11건)

EBV Encoded RNA 양성 위암에서 EBV Latent Membrane Protein 1 유전자 변화와 TGF-β1, TGF-βRII, p21,p16, E2F1, Thymidylate Synthase 및 NF-κB 단백 발현에대한 면역조직화학적 연구김명수, 최선주, 엄민섭, 성승훈, 김미동, 조미연, 박광화, 김대성pp. 176-184유방암종에서 p27kip1 단백의 세포 내 발현 위치와 예후와의 관련성홍숙희, 조세헌, 김대철, 홍영습pp. 185-192대장암 병리보고서 기재사항 표준화채양석, 김윤화, 김호근, 김영배, 송규상, 배한익, 장희진, 장희경, 장미수, 박철근, 김우호pp. 193-203한국인 전립선 선암종의 병리학적 분석: 83예의 지도화 분석이유정, 이강현, 홍은경, 김동일, 이희은, 이건국, 박원서, 원재경pp. 204-209곧창자 샘암종에서 세포주기 조절 단백 발현:수술 전 방사선화학 치료 반응 및 예후에 미치는 영향이교영, 최현주, 유진영, 정지한, 강석진, 신정하, 강창석pp. 217-224
원문 보기